The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals.
In the tender offer transaction, shareholders of Y-mAbs will receive $ $8.60 per share in cash, representing approximately $412 million in equity value. Y-mAbs insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Y-mAbs by imposing a significant penalty if Y-mAbs accepts a competing bid. We are investigating the conduct of the Y-mAbs board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
Join this Action